Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab-qyyp
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Trastuzumab-qyyp is a biosimilar monoclonal antibody to trastuzumab, marketed as Trazimera, developed by Pfizer for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.[1][2][5][10] It is a humanized IgG1 antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2/ErbB2), inhibiting HER2-mediated signaling, promoting antibody-dependent cellular cytotoxicity, and thereby suppressing proliferation and survival of HER2-overexpressing tumor cells.[1][3][7] Trazimera has been approved by the FDA as a biosimilar to the reference product Herceptin with no clinically meaningful differences in safety, purity, or potency, and is administered as an intravenous infusion using dosing and schedules aligned with trastuzumab for adjuvant and metastatic breast cancer and metastatic gastric cancer regimens.[1][5][6][11]
- Brand names
- Trazimera
- Other names
- trastuzumab-qyyp
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab-qyyp.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab-qyyp.